133 related articles for article (PubMed ID: 31581912)
61. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
62. Imaging cellular distribution of Bcl inhibitors using small molecule drug conjugates.
Giedt RJ; Sprachman MM; Yang KS; Weissleder R
Bioconjug Chem; 2014 Nov; 25(11):2081-5. PubMed ID: 25333750
[TBL] [Abstract][Full Text] [Related]
63. SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1.
Rega MF; Wu B; Wei J; Zhang Z; Cellitti JF; Pellecchia M
J Med Chem; 2011 Sep; 54(17):6000-13. PubMed ID: 21797225
[TBL] [Abstract][Full Text] [Related]
64. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
[TBL] [Abstract][Full Text] [Related]
65. 3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies.
Zhang Z; Wu G; Xie F; Song T; Chang X
J Med Chem; 2011 Feb; 54(4):1101-5. PubMed ID: 21235240
[TBL] [Abstract][Full Text] [Related]
66. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
Wan Y; Li Y; Yan C; Wen J; Tang Z
Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
[TBL] [Abstract][Full Text] [Related]
67. Systems analysis of phosphorylation-regulated Bcl-2 interactions establishes a model to reconcile the controversy over the significance of Bcl-2 phosphorylation.
Song T; Wang P; Yu X; Wang A; Chai G; Fan Y; Zhang Z
Br J Pharmacol; 2019 Feb; 176(3):491-504. PubMed ID: 30500985
[TBL] [Abstract][Full Text] [Related]
68. Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor.
Ku YY; Chan VS; Christesen A; Grieme T; Mulhern M; Pu YM; Wendt MD
J Org Chem; 2019 Apr; 84(8):4814-4829. PubMed ID: 30615835
[TBL] [Abstract][Full Text] [Related]
69. Discovery and development of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as Bcl-2/Mcl-1 inhibitors.
Liu R; Liu L; Yang X; Fang H
Bioorg Chem; 2019 Jul; 88():102938. PubMed ID: 31028992
[TBL] [Abstract][Full Text] [Related]
70. Targeting Bcl-2 Family Proteins: What, Where, When?
Senichkin VV; Pervushin NV; Zuev AP; Zhivotovsky B; Kopeina GS
Biochemistry (Mosc); 2020 Oct; 85(10):1210-1226. PubMed ID: 33202206
[TBL] [Abstract][Full Text] [Related]
71. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.
Shaw S; Bian Z; Zhao B; Tarr JC; Veerasamy N; Jeon KO; Belmar J; Arnold AL; Fogarty SA; Perry E; Sensintaffar JL; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2018 Mar; 61(6):2410-2421. PubMed ID: 29323899
[TBL] [Abstract][Full Text] [Related]
72. Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.
Winfield LL; Payton-Stewart F
Future Med Chem; 2012 Mar; 4(3):361-83. PubMed ID: 22393942
[TBL] [Abstract][Full Text] [Related]
73. Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety.
Deng H; Huang M; Liu H; Zhang H; Liu L; Gao B; Li X; Li J; Niu Q; Zhang Z; Luan S; Zhang J; Jing Y; Liu D; Zhao L
Bioorg Chem; 2022 Oct; 127():106018. PubMed ID: 35901526
[TBL] [Abstract][Full Text] [Related]
74. Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.
Pelz NF; Bian Z; Zhao B; Shaw S; Tarr JC; Belmar J; Gregg C; Camper DV; Goodwin CM; Arnold AL; Sensintaffar JL; Friberg A; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2016 Mar; 59(5):2054-66. PubMed ID: 26878343
[TBL] [Abstract][Full Text] [Related]
75. Discovery of 3,5-Dimethyl-4-Sulfonyl-1
Zhu PJ; Yu ZZ; Lv YF; Zhao JL; Tong YY; You QD; Jiang ZY
J Med Chem; 2021 Aug; 64(15):11330-11353. PubMed ID: 34342996
[TBL] [Abstract][Full Text] [Related]
76. Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.
Lebreton S; Jaunbergs J; Roth MG; Ferguson DA; De Brabander JK
Bioorg Med Chem Lett; 2008 Nov; 18(22):5879-83. PubMed ID: 18657422
[TBL] [Abstract][Full Text] [Related]
77. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.
Burke JP; Bian Z; Shaw S; Zhao B; Goodwin CM; Belmar J; Browning CF; Vigil D; Friberg A; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2015 May; 58(9):3794-805. PubMed ID: 25844895
[TBL] [Abstract][Full Text] [Related]
78. Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy.
Liu T; Wu Z; He Y; Xiao Y; Xia C
Eur J Med Chem; 2020 Sep; 201():112446. PubMed ID: 32563811
[TBL] [Abstract][Full Text] [Related]
79. Apoptosis therapy: driving cancers down the road to ruin.
Green DR; Walczak H
Nat Med; 2013 Feb; 19(2):131-3. PubMed ID: 23389605
[No Abstract] [Full Text] [Related]
80. Design, synthesis and structure–activity relationship studies of morpholino-1H-phenalene derivatives that antagonize Mcl-1/Bcl-2.
Li X; Liang X; Song T; Su P; Zhang Z
Bioorg Med Chem; 2014 Nov; 22(21):5738-46. PubMed ID: 25584387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
